Chemotherapy Supported by Autologous Hematopoietic Stem Cells

Recruiting now · Not applicable

Conditions studied: Ovarian Cancer

In brief

The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer. To explore the impact of stored haematopoietic stem cell support therapy on bone marrow protection after conventional chemotherapy for ovarian cancer in order to facilitate its clinical application.

Key facts

Study ID

NCT05401162

Run by

Chongqing University Cancer Hospital

People needed

40

Starts

2022-04-15

Expected to finish

2029-05-01

Last updated by the study team

2026-06-29

Who can join

Age: 18 and older, up to 60. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• 18-60 years old;
• there are chemotherapy indicators for ovarian cancer;
• ovarian cancer diagnosed by histopathology;
• recurrent and metastatic ovarian cancer;
• the Eastern Cooperative Oncology Group (ECOG) performance status score≤1;
• the expected survival time was more than 3 months;
• pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative;
• all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment;
• the subjects voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations;
• bone marrow function is good,ability to perform stem cell mobilisation and collection.

You may not qualify if…

• patients with bone marrow disease;
• central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology;
• patient has severe cardiac insufficiency;
• previous history of allogeneic stem cell transplantation or organ transplantation;
• patients with active bleeding and autoimmune thrombocytopenic purpura;
• patients with chemotherapy contraindications;
• positive for human immunodeficiency virus (HIV);
• acute or chronic active hepatitis B or hepatitis C infection.

Where it is running

• Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.